Bluesky Facebook Reddit Email

GLS2 shapes ferroptosis in hepatocellular carcinoma

10.19.23 | Impact Journals LLC

Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.


“[...] we hope that our findings will inform future decisions regarding treatment of liver disease.”

BUFFALO, NY- October 19, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on October 19, 2023, entitled, “ GLS2 shapes ferroptosis in hepatocellular carcinoma .”

In their new editorial, researchers Sawako Suzuki, Divya Venkatesh, Tomoaki Tanaka, and Carol Prives from Columbia University discuss ferroptosis regulation of GLS2 as a potential therapeutic strategy against liver diseases.

“More than a decade has passed since our group (1) as well as Hu et al., (2) identified glutaminase (GLS2) as a p53 target gene that promotes the tricarboxylic acid cycle (TCA) via α-ketoglutarate (αKG) and lowers oxidative stress via increasing glutathione (GSH) [ 1 , 2 ].”

Two years after this Dixon et al., [ 3 ] described a form of cell death they named ferroptosis which is caused by iron-mediated lipid peroxidation. Then, three years later, Gao et al., reported that GLS2 but not GLS1 is an inducer of ferroptosis in human cancer cells [ 4 ]. Ferroptosis had first been shown to be regulated by p53 via repression of SLC7A11 [ 5 ]. The circle was closed by a study from the Murphy group who reported that a cancer-related nonsynonymous mutation in p53 (P47S) is correlated with failure to either activate GLS2 expression or produce ferroptosis [ 6 ].

“Our recent study (Suzuki et al.) [ 7 ] has validated the ability of GLS2 to promote ferroptosis in murine models.”

Continue reading the full paper: DOI: https://doi.org/10.18632/oncotarget.28526

Correspondence to: Carol Prives

Email: clp3@columbia.edu

Keywords: ferroptosis, hepatocellular carcinoma, GLS2, p53, tumor suppression

About Oncotarget : Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget , visit Oncotarget.com and connect with us on social media:

Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28526 

Click here to subscribe to Oncotarget publication updates.

For media inquiries, please contact: media@impactjournals.com .

Oncotarget Journal Office

6666 East Quaker Str., Suite 1A

Orchard Park, NY 14127

Phone: 1-800-922-0957 (option 2)

###

Oncotarget

10.18632/oncotarget.28526

Observational study

People

GLS2 shapes ferroptosis in hepatocellular carcinoma

19-Oct-2023

Keywords

Article Information

Contact Information

Ryan Braithwaite
Impact Journals LLC
media@impactjournals.com

Source

How to Cite This Article

APA:
Impact Journals LLC. (2023, October 19). GLS2 shapes ferroptosis in hepatocellular carcinoma. Brightsurf News. https://www.brightsurf.com/news/80EQQXE8/gls2-shapes-ferroptosis-in-hepatocellular-carcinoma.html
MLA:
"GLS2 shapes ferroptosis in hepatocellular carcinoma." Brightsurf News, Oct. 19 2023, https://www.brightsurf.com/news/80EQQXE8/gls2-shapes-ferroptosis-in-hepatocellular-carcinoma.html.